Effect of the New Definition of Epilepsies of the ILAE of 2014 on the Diagnosis After the First Seizure
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital Marburg
About this trial
The present study is a prospective study on the development of seizure frequency, medication adherence, quality of life and cognitive performance after a first epileptic seizure using the new diagnostic criteria for epilepsy of the International League Against Epilepsy of 2014 at the time of diagnosis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Completion of the 18th year of life
first epileptic seizure
Ability to understand the patient information and to give written consent
Written consent for voluntary participation in the study
Disqualifiers
Chronic drug or alcohol abuse in the last two years
Trial population
adult patients with an nunprovoked epileptic seizure
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Rate of seizure recurrency
Seizure recurrency is recorded 6 months, 1 year, 3 years, 5 years and 10 years after the first seizure
Time frame
10 YearsSecondary outcomes
1
employment
Currently working as employee or independent, retirement or long-time sick-leave at the first attack, after 6 months, 1, 3, 5 and 10 years.
Time frame
10 years2
Salary
Gross salary in Euro at the first attack, after 6 months, 1, 3, 5 and 10 years.
Time frame
10 years3
Driving restriction
Fitness to drive (yes/no) is assessed after the first attack, after 6 months, 1, 3, 5 and 10 years.
Time frame
10 Years4
Verbale Lern- und Merkfähigkeitstest
Verbale Lern- und Merkfähigkeitstest - VLMT (Helmstaedter, Lendt, \& Lux, 2001) at baseline and then after 1 years, 5 years and 10 years after the first seizure: 0 to 135 points, O worst, 135 best possible result.
Time frame
10 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov